TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival

Br J Cancer. 2004 Feb 9;90(3):678-85. doi: 10.1038/sj.bjc.6601537.


We conducted the present study to evaluate the frequency and prognostic importance on long-term survival of TP53 mutations and TP53 protein accumulation in a cohort of 178 patients with early-stage ovarian carcinomas. TP53 mutations scored as aberrant temporal temperature gradient gel electrophoresis pattern from all exons were observed in 39.9% of the tumours. Full screening of exons 5-8, followed by sequencing, was successful in 135 cases, and 48 mutations altering the protein were detected in 39 cases (28.9%). TP53 mutations were slightly less common in the Federation of Gynecologists and Obstetricians stage IA than in IB/IC (P=0.05). No significant correlations with histological type, grade of differentiation, DNA ploidy status or age at diagnosis were found. TP53 protein accumulation analysed by immunohistochemistry was found in 32.6% of all tumours, and was a poor predictor of TP53 mutations with 56.4% sensitivity, 77.1% specificity, 50% positive predictive value and 81.3% negative predictive value. Neither TP53 mutations nor TP53 protein accumulation influenced the prognosis significantly in this group of patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cohort Studies
  • DNA Mutational Analysis
  • DNA, Neoplasm
  • Electrophoresis, Gel, Two-Dimensional
  • Exons
  • Female
  • Genes, p53 / genetics*
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology*
  • Ploidies
  • Predictive Value of Tests
  • Prognosis
  • Survival Analysis
  • Tumor Suppressor Protein p53 / analysis
  • Tumor Suppressor Protein p53 / genetics*


  • DNA, Neoplasm
  • Tumor Suppressor Protein p53